? Methodological issues and evidence of malfeasance in research purporting to show thimerosal in vaccines is safe.
Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later.
“There was a small, but statistically significant association between early thimerosal exposure and the presence of tics in boys.”
Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.
“Consistent significantly increased rate ratios were observed for autism, autism spectrum disorders, tics, attention deficit disorder, and emotional disturbances with Hg exposure from TCVs.”
? A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.
“Phase one showed significantly increased risks for autism, speech disorders, mental retardation, personality disorders, and thinking abnormalities reported to VAERS following thimerosal-containing DTaP vaccines in comparison to thimerosal-free DTaP vaccines. Phase two showed significant associations between cumulative exposures to thimerosal and the following types of NDs: unspecified developmental delay, tics, attention deficit disorder (ADD), language delay, speech delay, and neurodevelopmental delays in general.”